Sedana Medical: The ICU Turnaround Is Working; The FDA Is Still the Binary
Q3 growth and a smaller cash burn validate the ex-U.S. engine, but April 2027 remains the real catalyst.
SEDANA.ST · Earnings Call · 2026-10-22
Back to growth, but not yet out of the woods
Sedana Medical's Q3 2026 report has a clean headline: growth returned. Net sales reached SEK 44.2 million, up 7% at constant exchange rates, and management calls it the best third quarter in company history—no small claim for a seasonally weak period when ICU respiratory patients are scarce. The mix mattered: other direct markets grew 11%, distributor markets 27%, and contract manufacturing jumped 47%, helped by a shipment delayed from June into July. That timing boost is the flip side of Q2's soft print, so investors should not annualize it. Still, the direction is real: “Group sales grew 7% at constant exchange rates in the third quarter, with Germany improving considerably and all of our other businesses continuing to grow.” — Johannes Doll, CEO · 2026-10-22 The profitability picture is less clean. Group EBITDA was negative SEK 7 million, and the Ex U.S. business remained positive year-to-date at roughly SEK 3 million—a genuine achievement after years of restructuring. Cash burn fell to about SEK 14 million in Q3 from roughly SEK 30 million in Q2 as the intensive NDA submission phase passed. Sedana ended the quarter with SEK 40 million of cash and an undrawn SEK 50 million credit facility, leaving available funds around SEK 92 million. That is enough to get through the review period, but it is not a fortress balance sheet; the company still needs the U.S. approval to change its scale.Germany: execution versus the respiratory cycle
The most important commercial number is Germany. After an 18% decline in local currency in the first half, Q3 was down only 2%—close to last year. Year-to-date Germany is still down 40% in local currency, so this is a deceleration in the decline, not a recovery. Management attributes the improvement to two forces: easier comparisons in ICU caseloads and an acceleration program under new sales leadership. The program is explicitly about high potential accounts—the majority of German ICU hospitals are already customers, so growth must come from deeper penetration, not new logos. Priority accounts grew above the national average in Q3, which is the first evidence the approach is working. But the company is not yet growing nationally, and the market remains tied to ICU patient volumes. “After a decline of 18% in the first half of the year, we are now at -2% in Q3, so very close to last year's levels.” — Johannes Doll, CEO · 2026-10-22 The honest caveat came immediately after: “Year-to-date, we are still down 40% in local currencies, which is of course not where we want to be, but the trend is clearly moving in the right direction now.” — Johannes Doll, CEO · 2026-10-22 The rest of the direct markets were mixed. Spain slowed because Q3 is seasonally weak and summer staffing puts more junior doctors in ICUs; France was the fastest grower on uptake across the 38-hospital AP-HP network and a renewed UniHA tender listing; the U.K. grew only modestly. This is a company-specific execution story, not a sector-wide recovery. The global tape has plenty of medical-device and biotech names leaning on regulatory catalysts, but few are talking about inhaled ICU sedation. Sedana's language is its own.The binary: a PDUFA date and a nuanced evidence base
The real event is regulatory. The FDA accepted Sedana's NDA and set a PDUFA date of April 16, 2027. Management estimates the U.S. market at at least $1 billion, or SEK 10 billion–12 billion, roughly three times the potential of its current direct markets. At German penetration levels, U.S. sales could approach SEK 1.5 billion. The Early Access Program is live at three hospitals, with three more initiating in Q4 and a handful in early 2027; ten hospitals have expressed interest. That is useful launch preparation, not revenue. The tape agrees that PDUFA dates are a tradeable theme: PDUFA target action date shows up among the global 360-day advancers, and expanded access program is also a positive cluster. But Sedana is a micro-cap with a binary outcome, and management does not pretend otherwise.The clinical evidence is supportive but not a slam dunk. INSPiRE-ICU1 and 2 met the primary endpoint of non-inferiority to propofol, with greater opioid reduction, fast wake-up, and one more ICU-free day. The newly published SAVE-ICU study in JAMA is more nuanced: in acute hypoxemic respiratory failure patients, hospital mortality was 42.5% for isoflurane versus 43.8% for IV sedation—not statistically significant—though the three-month difference was 3.4% in isoflurane's favor. Peter Sackey framed it as a counterweight to last year's SESAR sevoflurane study, and Sedana's own pooled INSPiRE AHRF subgroup showed 30-day mortality of 21.8% for isoflurane versus 28% for propofol, also not statistically significant. “The results showed 42.5% hospital mortality for isoflurane versus 43.8% for IV... None of these results were statistically significant...” — Peter Sackey, CMO · 2026-10-22 The commercial case rests on opioid-sparing, rapid elimination, and ICU throughput—not a proven mortality benefit.Every FDA review involves some uncertainties and approval is not a given, but so far we have had a constructive dialogue with the agency and we are responding to their questions as the review progresses.